Lv5
854 积分 2022-06-23 加入
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
3天前
已完结
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1
17天前
已完结
P1.11.28 Nomogram and Effectiveness of Bone-Modifying Agents in Advanced Driver-Negative NSCLC: A Retrospective Real-World Study
20天前
已关闭
Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study
20天前
已关闭
LBA73 Final overall survival (OS) and safety analysis of the phase III ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)
1个月前
已关闭
First-in-human global multi-center study of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancer
1个月前
已完结
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial
1个月前
已完结
Pembrolizumab-induced lipodystrophy following pathological complete response in triple-negative breast cancer
1个月前
已关闭
Abstract PS19-10: Preclinical head-to-head comparison of CDK4/6 inhibitor activity toward CDK4 vs CDK6
1个月前
已关闭
Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer
1个月前
已完结
皖公网安备34019202002308
